China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its Carteyva (relmacabtagene autoleucel injection) in first-line high-risk large B-cell lymphoma. The first patient has already completed reinfusion therapy, marking a significant step in the study’s progress.
Previous Study Results
The pivotal RELIANCE study previously demonstrated that Carteyva had good safety and excellent efficacy in patients with recurrent/refractory large B-cell lymphoma who have received at least second-line treatment. This success laid the foundation for further exploration of the drug’s potential as a first-line treatment.
Current Study Design
The current open, one-arm, multi-center, investigator-initiated trial (IIT) in China is designed to assess the effectiveness and safety of Carteyva as a first-line treatment for adult patients with high-risk large B-cell lymphoma. This expansion of the study aims to broaden the drug’s application and benefit more patients at an earlier stage of the disease.
Product Profile
Relmacabtagene autoleucel is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics. It has been approved in China to treat adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and adult patients with follicular lymphoma that is refractory or that has relapsed within 24 months of second-line or above systemic treatment (r/r FL).
Significance of the Study
The initiation of this clinical study highlights JW Therapeutics’ commitment to advancing innovative treatments for lymphoma patients. By exploring Carteyva as a first-line therapy, the company aims to improve patient outcomes and expand the therapeutic options available for high-risk large B-cell lymphoma.-Fineline Info & Tech
